Bioheart, a developer of cell-based therapies for cardiovascular diseases, has been granted FDA approval to proceed with a Phase I clinical trial for a potential congestive heart failure treatment.
In last week’s Sentinel, OneMedPlace reported that Symphony Medical had initiated a Phase II clinical trial of their Plexisyl-AF device to treat atrial fibrillation.
Symphony Medical, a developer of novel biopolymer technologies for cardiac disorders, has successfully used its flagship Algisyl-LVR technology to treat their first human patient.
Copyright © 2024 | WordPress Theme by MH Themes